Even in NSCLC, where the compounds were approved, median response rates were in the 6–7 month range before relapse occurred, indicating that the vast majority of tumors develop resistance to single-agent KRAS G12C inhibitors [51,95]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.